Trinean to In-License PerkinElmer Technology
News Feb 04, 2013
Under the agreement, Trinean obtained a license for the design and development of microfluidic cartridges and instruments in the field of UV/VIS quantification of lightabsorbing substances for certain life sciences research applications.
“We are very pleased with this agreement between PerkinElmer and Trinean. The combined IP from Trinean and PerkinElmer will boost the expansion of our platform for DNA, RNA and protein quantification and quality control," said Philippe Stas, CEO of Trinean. "Our microfluidic chips generate high quality UV/Vis spectral absorbance profiles of bio-molecules. They are designed to meet the requirements of labs requiring speed and minimal sample usage. Our unmatched large measurement range allows quantification of undiluted protein samples in real-time thereby significantly shortening the purification process.”
"The use of microfluidics for UV/Vis spectrometry is an exciting market development," said Kevin Hrusovsky, Life Sciences President, PerkinElmer. "We continue to leverage our microfluidics portfolio through licensing collaborations such as our agreement with Trinean to extend our market reach and create additional revenue opportunities."
Microanalysis of Biological Samples for Early Disease DetectionNews
A group of researchers from Osaka University has now developed a nonlinear optical crystal (NLOC) chip, which combines THz waves with a microfluidic device, utilizing the close proximity of the THz wave source and the solution of interest in a microchannel.READ MORE
Novel Green Chemistry Method Improves Pharmaceutical Manufacturing EfficiencyNews
About 70 percent of pharmaceuticals are manufactured using palladium-driven catalytic processes that are either fast or efficient - but not both. Researchers have now developed a green chemistry method that combines aspects of both processes to improve efficiency at a minimal cost of processing time.READ MORE
Radioprotective Drugs Assessed Using Human Gut Organ-on-a-ChipNews
Researchers have published a study using an organ-on-a-chip (Organ Chip) model of the human gut that reveals the intestinal blood vessel cells may play an important part in radiation-induced intestinal injury, and it confirms that a potential radioprotective drug, dimethyloxaloylglycine (DMOG), suppresses the intestine’s responses to radiation injury.READ MORE
Comments | 0 ADD COMMENT
Next Gen Regenerative Medicine & Tissue Engineering
May 29 - May 30, 2018